Mikhail Blagosklonny’s Faith In Rapamycin As The Definitive Means To Human Rejuvenation Reaffirmed

Mikhail Blagosklonny has long been an advocate of rapamycin as the definitive means to achieve human rejuvenation. He realized while doing research on cancer treatment in St. Petersburg in the early 2000’s that the very properties that made rapamycin useful for slowing tumor growth, could be helpful in slowing the aging process. This was validated in 2009 when a National Institute of the Health-funded study came to the conclusion that rapamycin and its derivatives actually helped mice live longer. Read more on templeofthecave.com

Further validation came in 2014 on Christmas Eve when a paper published in the Science Transational Medicine, that is part of the Science Family of Journals that stated that a derivative of rapamycin called everolimus apparently improved the immune response of older adults if administered in small doses. For Blagosklonny who has long been a believer in the rejuvenating properties of rapamycin, this repeated validation is definitely very satisfying.

His background as a scientist who has studied cancer and aging helped him deduce something which can radically alter human longevity. An MD and Ph.D. in Experimental Medicine and Cardiology from the First Pavlov State Medical University of St. Petersberg, Blagosklonny became an associate professor of medicine at the New York Medical College in 2000. He followed this with a position as a senior scientist at the Ordway Research Institute. In 2009 he joined the Roswell Park Cancer Institute as a professor of oncology.

The varied exposure he got from working at different places made him the highly well-regarded professor that he is today. He has carried out how valuable research in the fields of anti-cancer drugs, and of course Biogerontology (underlying mechanisms of aging). That apart he is the Editor in Chief of Onco Target and Cell Cycle, other than being Associate Editor of Cancer Biology and Therapy. Of course, he is most well-known for his espousal of rapamycin as being integral to longevity research.

Blagosklonny happens to be the progenitor of the aging hyperfunction theory and expresses his views about cyclotherapy and chemotherapeutic engineering through his writing. He is at the same time intensely interested in oncology and holds the firm belief that it is possible to control both cancer and aging. His strident advocacy for the use of rapamycin is the main reason behind his belief.

With 300 research articles, chapters in books and reviews published under his name, he is quite a scientific heavyweight. Mikhail Blagosklonny has another distinction in that that he is also an Associate Editor with PLOS ONE, the International Journal of Cancer and the American Journal of Pathology. He really is one of the leading oncology researchers of the world, and according to Blagosklonny it really is his love for humankind that makes him work hard. Nothing would please him more than helping create communities that are disease free. Check Mikhail’s profile in LinkedIn

As regards his passion for increasing human longevity, there would not be a person alive who wouldn’t want to live longer, Blagosklonny is the first one who believed it was possible and actually suggested how that might be.